{"title":"高铝血症与口服柠檬酸盐和氢氧化铝有关。","authors":"B B Kirschbaum, A C Schoolwerth","doi":"10.1177/096032718900800108","DOIUrl":null,"url":null,"abstract":"<p><p>1. A hospitalized patient with renal failure receiving oral aluminium hydroxide was found to have a blood aluminium level of 3124 micrograms/l (116 mumol/l). 2. The extremely high aluminium concentration was attributed to the concurrent use of an oral citrate solution which converted the aluminium to a more soluble and absorbable form. 3. The combination of oral aluminium and citrate should be avoided in patients with poor renal function.</p>","PeriodicalId":13194,"journal":{"name":"Human toxicology","volume":"8 1","pages":"45-7"},"PeriodicalIF":0.0000,"publicationDate":"1989-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/096032718900800108","citationCount":"8","resultStr":"{\"title\":\"Hyperaluminaemia associated with oral citrate and aluminium hydroxide.\",\"authors\":\"B B Kirschbaum, A C Schoolwerth\",\"doi\":\"10.1177/096032718900800108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>1. A hospitalized patient with renal failure receiving oral aluminium hydroxide was found to have a blood aluminium level of 3124 micrograms/l (116 mumol/l). 2. The extremely high aluminium concentration was attributed to the concurrent use of an oral citrate solution which converted the aluminium to a more soluble and absorbable form. 3. The combination of oral aluminium and citrate should be avoided in patients with poor renal function.</p>\",\"PeriodicalId\":13194,\"journal\":{\"name\":\"Human toxicology\",\"volume\":\"8 1\",\"pages\":\"45-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1989-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/096032718900800108\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human toxicology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/096032718900800108\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/096032718900800108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Hyperaluminaemia associated with oral citrate and aluminium hydroxide.
1. A hospitalized patient with renal failure receiving oral aluminium hydroxide was found to have a blood aluminium level of 3124 micrograms/l (116 mumol/l). 2. The extremely high aluminium concentration was attributed to the concurrent use of an oral citrate solution which converted the aluminium to a more soluble and absorbable form. 3. The combination of oral aluminium and citrate should be avoided in patients with poor renal function.